Memory-network avoidance PCI was feasible beyond hippocampal sparing in limited-stage SCLC
VMAT-based PCI spared additional memory-network structures while maintaining whole-brain coverage in two patients with limited-stage SCLC.
VMAT-based PCI spared additional memory-network structures while maintaining whole-brain coverage in two patients with limited-stage SCLC.
Model-predicted microscopic glioblastoma spread could be incorporated into clinically deliverable plans, but dose-painting accuracy deteriorated as target complexity increased.
A phase I study safely escalated five-fraction stereotactic boosts to 30-35 Gy after recent prior radiotherapy, with 86.5% one-year local control.
A best MRI model reached AUC 0.91, but across 366 configurations radiomics did not consistently outperform a simple clinical model.
Ten-year biochemical control was 64.7% after salvage proton therapy, with 3.2% late grade 3 genitourinary toxicity.
Grade ≥3 mucositis at week 6 occurred in 11.1% with benzydamine versus 70.6% with standard care.
Accumulated gastrointestinal doses were generally lower than planned, while higher small-bowel dose showed exploratory associations with diarrhoea after MR-guided SABR.
MRI radiomics predicted VEGFA expression with validation AUC 0.718, while high VEGFA independently correlated with worse overall survival.
NRF2 directly activated WNT5A, sustaining β-catenin signaling, cancer stemness and radioresistance across esophageal cancer models.
Reduced-volume MR-guided RT caused no grade ≥3 toxicity, but two of ten patients developed in-field recurrence after five-fraction treatment.
FLASH protons largely preserved ocular structure and retinal function after 24 Gy while maintaining short-term tumor control in mice.
Spatially fractionated radiotherapy relieved symptoms in 91.7% of patients with bulky advanced tumors without reported grade ≥3 toxicity.
Hybrid ultra-high and conventional dose-rate irradiation retained FLASH sparing in mice, but protection diminished as the ultra-high-rate dose contribution decreased.
Yttrium-90 radioembolization achieved 67% objective response and 100% disease control in 12 patients with SDH-deficient GIST liver metastases.
Patients aged ≥75 years with CIRS-G ≥7 had median overall survival of 16 months after definitive chemoradiotherapy.